Dr. Xiaoxiao Zhong is a dedicated molecular biologist and medicine doctor at The Third Xiangya Hospital of Central South University 🏥. Her expertise lies in metabolic and glandular disorders, particularly breast cancer, where she employs multi-omics data analysis and in vitro assays to uncover dysregulated metabolic pathways and tumor microenvironment (TME) dynamics. Dr. Zhong bridges computational biology with wet-lab validation, focusing on biomarker discovery and translational oncology. Her work illuminates the complex interplay between immune and stromal components in cancer, contributing to the advancement of precision medicine. 🔬
Professional profile👤
ORCID
Scopus
Strengths for the Awards✨
Dr. Xiaoxiao Zhong demonstrates a strong research profile in the field of molecular biology, particularly focusing on metabolic disorders and tumor microenvironment (TME) remodeling in breast cancer. Her approach integrates bioinformatics and experimental biology, using tools like WGCNA and LASSO Cox regression to generate prognostic biomarkers, such as the 22-gene TMERS signature. This multidimensional methodology reflects a comprehensive understanding of systems biology and its translational applications in oncology.
Her contributions to identifying glycosylation-driven immune regulators like KLRB1, and validating their function in suppressing cancer progression, suggest originality, relevance, and clinical potential. The publication of 7 SCI/Scopus-indexed journal articles, along with 16 research projects and collaboration with national-level programs, further establishes her as a promising researcher making meaningful strides in precision medicine.
🎓 Education
Dr. Xiaoxiao Zhong received her medical degree with a specialization in molecular biology from Central South University 🎓. During her academic journey, she focused on cancer genomics, tumor immunology, and systems biology, acquiring hands-on expertise in high-throughput data interpretation and laboratory assays. Her continuous learning path has empowered her to translate molecular insights into clinical relevance, with a strong foundation in both theory and application.
💼 Experience
With a rich background in clinical and research settings, Dr. Zhong has successfully led or contributed to 16 research projects, including collaborations with the National Natural Science Foundation of China. She has been involved in 8 consultancy and industry-related projects, demonstrating her ability to bridge scientific innovation and real-world application. As a reviewer for Case Reports in Obstetrics and Gynecology, Dr. Zhong also plays a role in shaping scientific discourse. Her work environment blends rigorous experimentation with sophisticated bioinformatic modeling. 🔍
Dr. Zhong’s primary research interests revolve around tumor microenvironment (TME) remodeling, metabolic disorders, and translational oncology. She focuses on glycosylation-driven mechanisms, immune-stromal crosstalk, and prognostic modeling through multi-omics integration. Her research aims to dissect cellular heterogeneity and identify novel therapeutic and diagnostic targets in breast cancer. By leveraging both in silico and in vitro methodologies, she seeks to contribute to personalized medicine and improved patient outcomes.
🏅 Awards
Dr. Zhong is nominated for the Best Researcher Award 🏆 for her impactful contributions to cancer biology, particularly her development of a 22-gene TME-risk signature (TMERS) in breast cancer that has demonstrated strong prognostic value. Her identification of immune-regulatory glycosyltransferase genes and validation of KLRB1 as a tumor suppressor highlight her role in advancing the field of translational oncology. Her research is both innovative and clinically relevant, reinforcing her standing as an emerging leader in molecular medicine.
📚 Publications
1. Glycosylated protein-related microenvironmental features in breast cancer are associated with patient prognosis
-
Publication Year: 2025
-
Authors: Xiaoxiao Zhong, Jiaxuan Han, Huan Li, Xiangyu Shen, Bowen Yu, Ting Chen, Haobing Li, Jun Li, Jin Pang, Liyuan Qian, et al.
-
Journal: Mammalian Genome
-
DOI: 10.1007/s00335-025-10137-9
2. PCMT1 confirmed as a pan-cancer immune biomarker and a contributor to breast cancer metastasis
3. Interpretable machine learning model based on the systemic inflammation response index and ultrasound features can predict central lymph node metastasis in cN0T1–T2 papillary thyroid carcinoma
-
Publication Year: 2023
-
Authors: Jin Pang, Mohan Yang, Jun Li, Xiaoxiao Zhong, Xiangyu Shen, Ting Chen, Liyuan Qian
-
Journal: Gland Surgery
-
DOI: 10.21037/gs-23-349
4. Targeting survivin with Tanshinone IIA inhibits tumor growth and overcomes chemoresistance in colorectal cancer
-
Publication Year: 2023
-
Authors: Yaoquan Cao, Haibo Tang, Guohui Wang, Pengzhou Li, Zhi Song, Weizheng Li, Xulong Sun, Xiaoxiao Zhong, Qianqian Yu, Shaihong Zhu, et al.
-
Journal: Cell Death Discovery
-
DOI: 10.1038/s41420-023-01622-8
5. Breast cancer combined with contralateral neck lymph node metastasis: a case report
-
Publication Year: 2022
-
Authors: Xiaoxiao Zhong, Fengjiao Ding, Liyuan Qian, Wei Wu, Yanguang Wen, Boni Ding
-
Journal: Diagnostic Pathology
-
DOI: 10.1186/s13000-022-01236-1
6. Identification of N6-Methyladenosine-Related LncRNAs for Predicting Overall Survival and Clustering of a Potentially Novel Molecular Subtype of Breast Cancer
-
Publication Year: 2021
-
Authors: Xiaoxiao Zhong, Jun Li, Xin Wu, Xianrui Wu, Lin Hu, Boni Ding, Liyuan Qian
-
Journal: Frontiers in Oncology
-
DOI: 10.3389/fonc.2021.742944
✅ Conclusion
In summary, Dr. Xiaoxiao Zhong is an exceptional early-career researcher who blends scientific curiosity with technological rigor 🌟. Her contributions to cancer biology, particularly in decoding the tumor microenvironment and discovering novel biomarkers, have the potential to revolutionize prognostic models and therapeutic strategies. Through her dedication, interdisciplinary approach, and impactful publications, Dr. Zhong stands as a worthy nominee for the Best Researcher Award, representing the future of precision oncology.🏅
